Atazanavir/cobicistat

Last updated
Atazanavir/cobicistat
Combination of
Atazanavir HIV protease inhibitor
Cobicistat Cytochrome P450 (CYP3A) inhibitor
Clinical data
Trade names Evotaz
AHFS/Drugs.com Professional Drug Facts
License data
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

Atazanavir/cobicistat, sold under the brand name Evotaz, is a fixed-dose combination antiretroviral medication used to treat and prevent HIV/AIDS. [2] [3] It contains atazanavir and cobicistat. [2] [3] [4] Atazanavir is an HIV protease inhibitor and cobicistat is an inhibitor of cytochrome P450 (CYP) enzymes of the CYP3A family. [2]

Contents

Atazanavir/cobicistat was approved by the Food and Drug Administration (FDA) for medical use in United States in January 2015. [5] [6] It was authorized for medical use in the European Union in July 2015. [3]

Medical uses

Atazanavir/cobicistat is indicated for use in combination with other antiretroviral agents for the treatment of HIV‑1 infection in people weighing at least 35 kilograms (77 lb). [2] [3]

References

  1. ↑ "Evotaz 300 mg/150 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). Retrieved 9 July 2021.
  2. 1 2 3 4 5 "Evotaz- atazanavir and cobicistat tablet". DailyMed. Retrieved 25 May 2021.
  3. 1 2 3 4 5 "Evotaz EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 25 May 2021.
  4. ↑ Crutchley RD, Guduru RC, Cheng AM (2016). "Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection". HIV/AIDS: Research and Palliative Care. 8: 47–65. doi: 10.2147/HIV.S99063 . PMC   4790521 . PMID   27022304.
  5. ↑ "U.S. Food and Drug Administration Approves Bristol-Myers Squibb's Evotaz (atazanavir and cobicistat) for the Treatment of HIV-1 Infection in Adults" (Press release). Bristol-Myers Squibb. Archived from the original on 2020-08-08. Retrieved 2018-06-28.
  6. ↑ "Evotaz (atazanavir and cobicistat) Tablet". U.S. Food and Drug Administration (FDA). 15 April 2016. Archived from the original on May 2, 2016. Retrieved 25 May 2021. "Summary Report" (PDF).


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.